Genedrive shareholders back fundraising as company expands pharmacogenetic footprint

The latest update is out from Genedrive ( (GB:GDR) ).

Genedrive plc, a Manchester‑based pharmacogenetic testing specialist, develops and commercialises rapid, low‑cost point‑of‑care genetic tests that enable clinicians to tailor drug choice and dosage, with a focus on emergency care. Its Genedrive MT‑RNR1 ID Kit for neonatal intensive care and CYP2C19 ID Kit for stroke patients, both delivered via single‑use ambient‑stable cartridges on its own thermocycler platform, have been recommended by NICE for use across the UK NHS.

At a General Meeting held on 9 March 2026, shareholders of Genedrive plc passed all resolutions supporting its previously announced fundraising, paving the way for the admission of new subscription, placing, open offer and loan conversion shares to trading on 10 March. Following admission, the company will have 1,605,568,256 ordinary shares in issue, significantly enlarging its capital base and providing funding flexibility to pursue its commercial growth strategy in the point‑of‑care pharmacogenetics market.

The most recent analyst rating on (GB:GDR) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.

Spark’s Take on GB:GDR Stock

According to Spark, TipRanks’ AI Analyst, GB:GDR is a Neutral.

The score is held back primarily by weak financial performance—large ongoing losses, sustained cash burn, and a shrinking equity base despite minimal debt. Technicals are moderately supportive with price above key moving averages and positive MACD, but elevated RSI signals near-term overheating risk. Valuation remains challenging due to negative earnings (negative P/E).

To see Spark’s full report on GB:GDR stock, click here.

More about Genedrive

Genedrive plc is a UK‑based pharmacogenetic testing company focused on low‑cost, rapid, point‑of‑care diagnostics that identify genetic variants to guide personalised medicine, particularly in time‑critical emergency care. Its flagship Genedrive MT‑RNR1 ID Kit for neonatal antibiotic decisions and CYP2C19 ID Kit for stroke patients run on a proprietary thermocycler platform, use ambient‑stable disposable cartridges, and have been recommended for use in the UK NHS as part of a growth strategy built on in‑market sales, geographic expansion, portfolio development and strategic M&A.

The company positions itself at the forefront of point‑of‑care pharmacogenetic testing in emergency healthcare, targeting safer, more effective and rapid treatment decisions by informing how individual genetics affect response to medicines. Working from its Manchester facilities and in collaboration with NHS partners, Genedrive aims to scale adoption of its tests, which currently face limited direct competition in their respective indications, strengthening its standing in precision medicine diagnostics.

Average Trading Volume: 6,186,959

Technical Sentiment Signal: Sell

Current Market Cap: £11.6M

See more insights into GDR stock on TipRanks’ Stock Analysis page.